Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
tc
9
×
health
bio
editas medicine
jennifer doudna
non-coding rna
repetitive dna sequences
biology
biotechnology
science
american biochemists
berkeley college of chemistry faculty
column
crispr therapeutics
crystallographers
emerging technologies
enzymes
gene editing
harvard university alumni
howard hughes medical investigators
intellia therapeutics
living people
members of the united states national academy of sciences
molecular biology
nobel prize
university of california
yale department of molecular biophysics & biochemistry faculty
1861 establishments in massachusetts
1963 births
23andme
agriculture
american women scientists
applied genetics
association of american universities
berkeley
bill gates
bioethics
biological engineering
biotech
What
editing
9
×
gene
crispr
read
technology
berkeley
biotech
cas
doudna
institute
jennifer
patent
today
berkeley’s
broad
california
century
chemistry
discovery
going
harvard
industry
inventor
medicine
molecular
nobel
prize
public
think
university
using
went
actually
advances
alexandria
ambitious
andme
award
awards
believe
Language
unset
Current search:
editing
×
tc
×
@techcrunch.com
2 years ago
How Colossal sold investors on a quest to resurrect a woolly mammoth
@techcrunch.com
7 years ago
CRISPR-Cas9 inventor Jennifer Doudna’s plans on moving forward, genetically modifying humans
@techcrunch.com
7 years ago
Judge rules CRISPR-Cas9 patents belong to Broad Institute of Harvard and MIT
@techcrunch.com
7 years ago
CRISPR loses Nobel to tiny machines
@techcrunch.com
7 years ago
CRISPR will have to wait for that Nobel prize
@techcrunch.com
7 years ago
Jennifer Doudna, inventor of gene editing technology CRISPR Cas9, is coming to Disrupt
@techcrunch.com
7 years ago
Reshaping human health and changing lives through gene editing
@techcrunch.com
8 years ago
Innovation in genomics and the future of medtech
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute
